 AVROBIO Inc NASDAQ: AVRO dropped by 30 after announcing it was changing its portfolio priorities to concentrate on other clinical-stage pipeline programs. The company plans to deprioritize the Fabry program because of several reasons, including new clinical findings from the most recent patients given the Phase II FAB-GT drug candidate. 